Antisense and/or immunostimulatory oligonucleotide therapeutics

Area of Science:

• Molecular Biology
• Medicinal Chemistry
• Immunology

Background:

• Antisense technology targets disease-causing genes via mRNA binding.
• First-generation phosphorothioate antisense oligonucleotides (ASOs) face limitations due to sequence motifs causing side effects.
• CpG dinucleotides in ASOs can trigger immune responses, presenting both challenges and therapeutic opportunities.

Purpose of the Study:

• To review the advancements in antisense technology.
• To discuss the limitations of first-generation ASOs and the development of second-generation ASOs.
• To explore the therapeutic potential of CpG-containing oligonucleotides and their immunomodulatory activity.

Main Methods:

• Review of scientific literature on antisense technology and oligonucleotide therapeutics.
• Analysis of clinical trial data for first- and second-generation ASOs.
• Examination of medicinal chemistry approaches for modifying oligonucleotide therapeutics.

Main Results:

• Antisense technology has significantly progressed, with ASOs in clinical trials for cancer.
• Second-generation ASOs with chemical modifications aim to enhance safety and efficacy.
• CpG-containing oligonucleotides demonstrate immune-stimulating properties, being developed as a therapeutic modality.

Conclusions:

• Chemical modifications are crucial for overcoming first-generation ASO limitations.
• Second-generation ASOs, including mixed-backbone designs, are under clinical evaluation.
• Fine-tuning the immunomodulatory activity of CpG oligonucleotides through medicinal chemistry enables the design of targeted oligonucleotide therapeutics.